

SCIENTIFIC PROGRAM 2026

Maison de la Chimie, Paris January 19-21, 2026

1st annual meeting

With the scientific support of











Welcome to the Paris International Liver Meeting 2026!

Dear Colleagues,

It is our great pleasure to welcome you on behalf of the Scientific Committee to the Paris International Liver Meeting, which will be held in the beautiful city of Paris from January 19-21. 2026.

This meeting will bring together leading experts, clinicians, researchers, biopharmaceutical industry and healthcare professionals from around the world to share the latest clinically relevant advances in the management and treatment of chronic liver diseases. Also, this meeting will bring together all important stakeholders to interact and share practical perspectives about important liver diseases.

Over three days, the program will explore and provide up-to-date short reviews by the best experts on the different aspects of clinical hepatology, including MASLD, MetALD, ALD, viral hepatitis, cholestatic liver diseases, HCC and complications of cirrhosis.

Over the course of the meeting, you will have the opportunity to interact with thought leaders, attend thought-provoking sessions, contribute to discussions and interact with leading biopharmaceutical leaders in liver disease that we hope will not only deepen your knowledge, but also be helpful in your clinical practice.

Join us at the prestigious Maison de la Chimie for a fruitful and productive meeting!

Laurent Castera, MD PhD

Zobair M. Younossi, MD

Co-Chairs, Paris International Liver Meeting





MONDAY, 19 JANUARY - MORNING

08:00 - 08:20 AM	WELCOME DESK OPENING
08:20 - 08:30 AM	INTRODUCTION Laurent Castera (FR) & Zobair Younossi (US)
08:30 - 10:00 AM	SESSION 1: Hepatitis B – D Optimal Management Chairs: Pietro Lampertico (IT) & Sabela Lens (ES)
08:30-08:45 08:45-09:00	EASL/AASLD 2025 HBV guidelines Markus Cornberg (DE) HDV new insights from virology to epidemiology and natural history Maurizia Brunetto (IT)
09:00-09:15 09:15-09:30	HDV therapy: BLV monotherapy and combination Tarik Asselah (FR) HDV therapy: new antiviral therapies (phase 2 studies) Pietro Lampertico (IT)
09:30-10:00	Panel discussion (Moderator Sabela Lens)
10:00 - 11:00 AM	Obesity in the Metabolic Era: Global Burden, Treatment, and Clinical Integration Chairs: Laurent Castera (FR) & Zobair Younossi (US)
10:00-10:02	Opening Remarks Zobair Younossi (US)
10:02-10:12	Global Burden of Obesity and Associated Cardiometabolic Risks S. Zelber Sagi (IL)
10:12-10:27	Pharmacologic Treatment of Obesity John Wilding (UK)
10:27-10:42	Integrated Care Pathways for Obesity and Cardiometabolic Conditions: Creating the Metabolic Clinics Arya Sharma (CA)
10:42-11:00	Panel Discussion — Translating Evidence into Integrated Practice Moderated by Laurent Castera (FR)

Faculty (S. Zelber Sagi, John Wilding, and Arya Sharma)



MONDAY, 19 JANUARY - MORNING

11:00 - 11:20 AM	COFFEE BREAK
11:20 - 12:50 PM	SESSION 2: Advances in the Management of Cirrhosis Complications Chairs: Annalisa Berzigotti (CH) & Adrian Gadano (AR)
11:20-11:35	What new evidence and definitions have been further developed with Baveno VII and beyond Annalisa Berzigotti (CH)
11:35-11:50	Transjugular intrahepatic porto-systemic shunt (TIPS): Expanding Indications and Refining Risk Stratification Dominique Thabut (FR)
11:50-12:05	Acute Kidney Injury in Cirrhosis: an update from the ADQI and International Club of Ascites (ICA) Consensus Claire Francoz (FR)
12:05-12:20	New challenges in SBP prophylaxis: Beyond the guidelines Paolo Angeli (IT)
12:20-12:50	Panel Discussion (Moderator Adrian Gadano)



MONDAY, 19 JANUARY - AFTERNOON

01:00 - 02:00 PM WORKSHOPS

1 - How do I use new HBV markers in practice?

Nicola Pugliese (IT), Jean-Michel Pawlotsky (FR) & Alessio Aghemo (IT)

2 - How do I manage and treat HDV in my practice?

Elisabetta Degasperi (IT), Maria Buti (ES) & Tarik Asselah (FR)

3 - When should I consider liver transplantation in a patient with HCC?

Helena Hernandez-Evole (ES), François Durand (FR) & Jean- François Dufour (CH)

4 - MASLD and viral hepatitis (hepatitis B & C): is there an impact?

Lucia Parlati (FR), George Papatheodoridis (GR) & Yusuf Yilmaz (TR)

5 - How do I use NITs for treatment of MASH in 2026?

Paul Brennan (UK), Vlad Ratziu (FR) & Vincent Wong (HK)

02:00 - 02:30 PM COFFEE / DESSERTS

02:30 - 03:00 PM STATE OF THE ART LECTURE

Chair: Lawrence Serfaty (FR)

Fibrosis in MASH: A Surrogate for Mortality and Endpoint for

Treatment

Massimo Pinzani (IT)

03:00 - 04:00 PM SYMPOSIUM

04:00 - 04:30 PM COFFEE BREAK

04:30 - 06:00 PM SESSION 3: Advances in the Management of HCC

Chairs: Josep Llovet (ES-US) & Massimo Pinzani (IT)

04:30-04:45 Overview of Guidelines of HCC management (EASL, AASLD, ESMO)	04:30-04:45	Overview of	Guidelines of	HCC management	(EASL, AAS	SLD, ESMO)	
--	-------------	-------------	---------------	----------------	------------	------------	--

Josep M Llovet (ES-US)

04:45-05:00 Advances in the management of early/intermediate HCC

Thierry de Baère (FR)

05:00-05:15 Advances in the management of advanced HCC

Lorenza Rimassa (IT)

05:15-05:30 **Emerging therapies**

David Pinato (UK)

05:30-06:00 Panel discussion (moderator Massimo Pinzani)

06:00 PM CONCLUSION DAY 1

Laurent Castera (FR) & Zobair Younossi (US)



TUESDAY, 20 JANUARY - MORNING

08:30 - 10:00 AM	SESSION 4: MASLD Epidemiology, Economic Impact, and Risk Stratification Using NITs
	Chairs: Manolis Tsochatzis (UK) & Laurent Castera (FR)
08:30-08:45	Epidemiology and financial impact of MASH Zobair Younossi (US)
08:45-09:00	NIT algorithms for identifying high risk patients with MASH Jérôme Boursier (FR)
09:00-09:15	Non-invasive tests for treatment response in MASH Manolis Tsochatzis (UK)
09:15-09:30	Pulling it all together: the use of NITs in clinical practice of MASH Vincent Wong (HK)
09:30-10:00	Panel discussion (moderator Laurent Castera)
10:00 - 11:00 AM	SYMPOSIUM
11:00 - 11:20 AM	COFFEE BREAK
11:20 - 12:50 PM	SESSION 5: MASLD Treatment Chairs: Mazen Noureddin (US) & Vincent Wong (HK)
11:20-11:35	Lifestyle modifications for patients with MASH Shira Zelber-Sagi (IL)
11:35-11:50	Treatment of MASH-Co Morbidities (type 2 diabetes) Elisabetta Bugianesi (IT)
11:50-12:05	Current treatment of MASH Mazen Noureddin (US)
12:05-12:20	Future treatments of MASH: What is in the pipeline? Frank Tacke (DE)
12:20-12:50	Panel Discussion (moderator Vincent Wong, Michael Betel patient representative)



TUESDAY, 20 JANUARY - AFTERNOON

01:00 - 02:00 PM WORKSHOPS

1 - Management of pruritus and fatigue for patients with PBC

Olivier Roux (FR), Andreas Kremer (CH) & Ana Lleo (IT)

2 - How do I diagnose and manage portal hypertension in my clinic?

Elise Vuille-Lessard (CH), Pierre-Emmanuel Rautou (FR) & Thomas Reiberger (AT)

3 - What are the tips to implement diet and physical exercise in my practice?

Thomas Mouilllot (FR), Sébastien Czernichow (FR) & Shira Zelber-Sagi (IL)

4 - How to accurately estimate alcohol consumption over time in clinical practice?

Mads Israelsen (DK), Sven Francque (BE) & Christophe Moreno (BE)

5 - What are my preferred drugs to treat obesity or type 2 diabetes in a patient with MASLD?

Maurice Michel (GE), Cyrielle Caussy (FR) & Jean-François Gautier (FR)

02:00 - 02:30 PM COFFEE / DESSERTS

02:30 - 03:00 PM STATE OF THE ART

Advances in hepatic encephalopathy

Debbie Shawcross (UK)

03:00 - 04:00 PM SYMPOSIUM

04:30-04:45

04:00 - 04:30 PM COFFEE BREAK

04:30 - 06:00 PM SESSION 6: MetALD and ALD

Chairs: Maja Thiele (DK) & Christophe Moreno (BE)

Update on diagnosis of MetALD Maja Thiele (DK)

04:45-05:00	The natural history of MetALD Hannes Hagström (SE)
05:00-05:15	Update on ALD Ramon Bataller (ES)
05:15-05:30	Pharmaceutical and non-pharmaceutical treatment for MetALD and
	ALD Mark Thursz (UK)
05:30-06:00	Panel discussion (Christophe Moreno moderator)

06:00 PM CONCLUSION DAY 2

Laurent Castera (FR) & Zobair Younossi (US)



WEDNESDAY, 21 JANUARY - MORNING

09:00 - 10:00 AM SESSION 7: R&D - The drug pipelines presented by sponsors

(10 min each)

Chairs: Laurent Castera (FR) & Zobair Younossi (US)

10:00 - 10:30 AM COFFEE BREAK

10:30 - 11:45 AM SESSION 8: Current Optimal treatment and Future Innovations in

PBC and **PSC**

Chairs: Andreas Kremer (CH) & Ana Lleo (IT)

10:30-10:45 How to treat and assess risk in a patient with PBC? David Jones (UK)

10:45-11:00 How to treat and monitor a patient with PSC? Andreas Kremer (CH)

11:00-11:15 Future treatment for PBC and PSC Ana Lleo (IT)

11:15-11:45 Panel Discussion

11:45 - 12:15 PM SPECIAL LECTURE

Screening for liver disease in the general population: the LiverScreen

Story

Pere Gines (ES)

12:15 PM CONCLUSION DAY 3

Laurent Castera (FR) & Zobair Younossi (US)



Co-Chairs



Laurent CASTERA, MD, PhD FRANCE

Professor of Hepatology, Head of the NASH/MASH Program
Department of Hepatology, Hôpital Beaujon, AP-HP
INSERM UMR 1149, Centre de Recherche sur l'Inflammation Paris Montmartre,
Université Paris-Cité, Clichy, France



Zobair M YOUNOSSI, MD, MPH USA

Professor and Chairman, the Global NASH/MASH Council Center for Outcomes Research in Liver Disease 2411 | Street, Washington DC 20023, USA





Scientific Committee



Annalisa BERZIGOTTI, MD, PhD SWITZERLAND

Full Professor of Clinical Hepatology at the University of Berne and Chief of Hepatology and Co-Director of the Department of Visceral Surgery and Medicine of the Inselspital, University Hospital of Berne



Adrian GADANO, MD, PhD ARGENTINA

Head of the Research Department at the Hospital Italiano de Buenos Aires



Andreas KREMER, MD, PhD SWITZERLAND

Head of Hepatology and Vice Director of the Department of Gastroenterology and Hepatology, University Hospital Zurich



Pietro LAMPERTICO, MD, PhD ITALY

Full Professor in the Gastroenterology, Director of the Gastroenterology and Hepatology Division, Head of the "A. M. e A. Migliavacca" Center for Liver Disease at the Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, University of Milan



Josep LLOVET, MD, PhD SPAIN

Full Professor of Medicine and Director of the Liver Cancer Program at Icahn School of Medicine at Mount Sinai (New York - USA)

ICREA Research Prof at IDIBAPS-Hospital Clínic and Full Prof of Medicine-Hepatic

Oncology at the Univ. of Barcelona



Scientific Committee



Mazen NOUREDDIN, MD, MHSc USA

Professor of Medicine at the Lynda K. and David M. Underwood Center for Digestive Disorders J.C. Walter Jr. Transplant Center Sherrie & Alan Conover Center for Liver Disease & Transplantation at Houston Methodist Hospital



Massimo PINZANI, MD, PhD ITALY

Emeritus Professor of Medicine at University College London (UCL) (UK) Scientific Director of UPMC (University of Pittsburgh Medical Center)-ISMETT IRCSS in Palermo



Maja THIELE, MD, PhD DENMARK

Professor of Hepatology at Department of Gastroenterology and Hepatology, Odense University Hospital and University of Southern Denmark



Manolis TSOCHATZIS, MD, MSc UNITED KINGDOM

Professor of Hepatology and Consultant Hepatologist at the UCL Institute for Liver and Digestive Health, Royal Free Hospital in London



Vincent WONG, MD HONG KONG

Mok Hing Yiu Professor of Medicine and head of the Division of Gastroenterology and Hepatology at The Chinese University of Hong Kong



Faculty

FACULTY

AGHEMO Alessio ISRAELSEN Mads

ANGELI Paolo JONES David

ASSELAH Tarik KREMER Andreas

BATALLER Ramon LAMPERTICO Pietro

BERZIGOTTI Annalisa LENS GARCÍA Sabela

BETEL Michael LLEO Ana

BOURSIER Jérome LLOVET Josep

BRENNAN Paul MICHEL Maurice

BRUNETTO Maurizia MORENO Christophe

BUGIANESI Elisabetta MOUILLOT Thomas

BUTI Maria NOUREDDIN Mazen

CASTERA Laurent PAPATHEODIRIS George

CAUSSY Cyrielle PARLATI Lucia

CZERNICHOW Sébastien PAWLOTSKY Jean-Michel

CORNBERG Markus PINATO David

DE BAERE Thierry PINZANI Massimo

DEGASPERI Elisabetta PUGLIESE Nicola

DUFOUR Jean-François RATZIU Vlad

DURAND François RAUTOU Pierre-Emmanuel

FRANCOZ Claire REIBERGER Thomas

FRANCQUE Sven RIMASSA Lorenza

GADANO Adrian ROUX Olivier

GAUTIER Jean-François SERFATY Lawrence

GINES Pere SHARMA Arya

HAGSTRÖM Hannes SHAWCROSS Debbie

HERNANDEZ EVOLE Helena TACKE Frank





FACULTY

THABUT Dominique

THIELE Maja

THURSZ Mark

TSOCHATZIS Manolis

VUILLE LESSARD Elise

WONG Vincent

YILMAZ Yusuf

YOUNOSSI Zobair

WILDING John

ZELBER SAGI Shira